TrialChinese journal of cancer2016

Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.

Yun Leng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.